# Characteristics of the elderly in high-resolution computed tomography lung densitometry

Fumihiro Mitsunobu, Yasuhiro Hosaki, Kozo Ashida, Naofumi Iwagaki, Takuya Nagata, Makoto Fujii, Shingo Takata, Tadashi Yokoi<sup>13</sup>, Masanori Hamada<sup>13</sup>, and Yoshiro Tanizaki

Division of Medicine, <sup>13</sup>Division of Rehabilitation, Misasa Medical Center, Okayama University Medical and Dental School

ABSTRACT: To determine the characteristics of the elderly in high-resolution computed tomography (HRCT) lung densitometry, mean lung density (MLD) and relative area of the lungs showing attenuation values less than -950 HU (RAss) on HRCT were evaluated in nonsmoking control subjects (n = 80) and patients with asthma (n = 80) in relation to their age and pulmonary function. MLD was significantly decreased, and RA<sub>250</sub> was significantly increased with increasing age in both asthmatics and controls. The MLD values were significantly lower in asthmatics compared with controls in subjects aged between 60 and 69 years and over age 70. RA so values were significantly higher in asthmatics compared with controls in subjects aged between 50 and 59 years, between 60 and 69, and over 70. %FEV1 and FEV1/FVC were significantly decreased in elderly asthmatic patients over 70 years of age compared with the values in those under 49. Percent residual volume (%RV) was significantly larger in patients over 70 years of age than in those between 50 and 59, and under 49 years. RAsso was significantly larger in patients with steroid-dependent intractable asthma (SDIA) between 50 and 59 years of age, and between 60 and 69 compared with RA 950 in those without SDIA. However, RAsso did not differ significantly between SDIA and non-SDIA in patients over age 70. The results suggested that in %LAA of the lungs on HRCT was significantly increased in the elderly subjects with and without asthma, and it was significantly higher in the elderly asthmatics than the elderly controls.

Keywords: aging, high-resolution computed tomography, low attenuation area, mean lung density, pulmonary function

# Introduction

Asthma is characterized by airway inflammation, and an increase in airway smooth muscle<sup>1,2)</sup>, mucous gland hypertrophy<sup>2)</sup>, and reorganization of the extracellular matrix<sup>3)</sup> have been observed in the inflammatory process. Furthermore, airway reconstruction, such as bronchial wall thickening, bronchiectasis, emphysematous changes, and mosaic patterns of lung attenuation has been demonstrated by high-resolution computed tomography (HRCT) in patients with asthma<sup>4,53</sup>. Asthmatics with abnormal HRCT findings have been shown to have poorer lung function and less hyperresponsive bronchi than those with normal HRCT findings<sup>63</sup>.

In contrast, previous studies have shown that low attenuation areas (LAA) on CT scans in vivo represent macroscopic and/or microscopic emphysematous changes in the lungs of patients with chronic obstructive pulmonary disease (COPD) 7-15). For the analysis of CT images, a quantitative method using digital data as well as a visual assessment of the scan is currently available 7.15). Some studies have investigated the use of CT lung densitometry in nonsmoking asthmatic patients 16-21), and our previous study suggested that mean lung density (MLD) and relative area of the lungs showing attenuation values less than -950 HU (RA<sub>950</sub>) are significantly correlated with pulmonary function, patient age, and disease severity in nonsmoking asthmatic patients<sup>20)</sup>. We also reported that decreased CT lung density during asthma exacerbation is at least partially reversible, and changes of MLD and RA950 are related to the change in FEV<sub>1</sub> and residual volume<sup>21)</sup>. However, to our knowledge, the characteristics of asthma in the elderly have not been determined using HRCT. The purpose of this study was to investigate the

influence of aging on HRCT lung densitometry in patients with asthma and control subjects.

# Subjects and Methods

## **Subjects**

Eighty asthmatics (60 females and 20 males; mean age 58 years, range 19-80 years) and eighty healthy controls (55 females and 25 males; mean age 59 years, range 24-83 years) were recruited from Misasa Medical Center. Asthma was diagnosed according to the definition proposed by the American Thoracic Society<sup>20</sup>. All patients with asthma showed episodic symptoms of wheezing and coughing, and experienced symptomatic relief and reversible airway response with an accompanying increase in forced expiratory volume in one second (FEV<sub>1</sub>) exceeding 15% upon treatment with 3 2-adrenergic agonists. Asthmatics were stable with no changes in asthma symptoms and medication for at least 1 month, except for the use of shortacting inhaled 32-agonists. None of the subjects had a history of upper respiratory tract infection within the month prior to entry. Twentyfour of 80 patients had steroid-dependent intractable asthma (SDIA) and had been treated with glucocorticoids for more than 2 years. Control subjects were randomly selected from those voluntarily visiting our hospital for an annual medical examination. They had no historical or clinical evidence of allergic, respiratory or cardiovascular disease, had a normal chest radiograph, and normal values for spirometry.

All subjects were lifelong nonsmokers. The subjects underwent high-resolution chest CT scan and pulmonary function tests on the same day. Asthmatics and controls were classified into four groups according to their age:  $\leq 49$  years; 50-59 years; 60-69 years;  $\geq 70$  years. Each age group consisted of 20 asthmatics and 20 controls.

Atopy was evaluated by a combination of history of allergies, skin tests and the presence of serum IgE antibodies specific to the 12 common aeroallergens, including dust mites, pollens, molds, and animal danders. Serum-specific IgE was measured using the Pharmacia CAP <sup>R</sup> System (Pharmacia Diagnostics AB, Uppsala, Sweden). Atopic patients were defined as those who had a positive skin test and/or the presence of allergen-specific IgE.

Informed consent was obtained from all subjects. The study protocol was approved by the ethics committee of our institution.

## Pulmonary function tests

Pulmonary function tests were performed with a Chestac 33 (Chest Co., Tokyo, Japan). Forced vital capacity (FVC), FEV<sub>1</sub>, FEV<sub>1</sub>/FVC, residual volume (RV) using the helium dilution method and carbon monoxide diffusing capacity (DL<sub>co</sub>) using the single breath method were measured. The FVC, FEV<sub>1</sub> and RV measurements were expressed as a percentage of their predicted values (%FVC, %FEV<sub>1</sub> and %RV, respectively) according to the prediction equations of the Japanese Society of Chest Diseases<sup>230</sup>. DL<sub>co</sub> was also expressed as a percentage of the predicted values following the method of Nishida (%DL<sub>co</sub>). The ratio of FEV<sub>1</sub> to FVC (FEV<sub>1</sub>/FVC) was expressed as a percentage.

# Computed tomography

Each patient underwent noncontrast high-resolution computed tomography (HRCT) using a TOSHIBA Aquilion (TOSHIBA, Tokyo, Japan) scanner with 2-mm collimation, a scanning time of 1.0 seconds, a voltage of 120 kVp, and a current of 200 mA. All HRCTs were performed in supine patients following maximal inspiration. The images were reconstructed on a 32-cm field of view (FOV) using a standard algorithm (FC

10). Three HRCT scans were performed for determination of MLD and LAA; an upper section was obtained at the top of the aortic arch, a middle section was taken at the origin of the lower lobe bronchus, and a lower section was taken 3 cm above the top of the diaphragm, as described by Miniati et al. 240. The cut-off level between the normal lung density area and LAA was defined as -950 HU, and RA<sub>950</sub> was calculated using a method previously reported [6-21]. The MLD was calculated from the total crosssectional area of the six lung hemislices obtained at the three anatomical levels. Similarly, the lung area occupied by voxels with attenuation values lower than -950 HU (A<sub>950</sub>), obtained by summing the values of A<sub>950</sub> in each of the six hemislices, was expressed as a percentage of the total lung cross-sectional area (RA<sub>950</sub>). HRCT lung densitometry was performed for each subject by means of a dedicated software program from TOSHIBA.

#### Statistical Analysis

All statistical analyses were carried out using Stat View software (SAS Institute Inc., NC, USA). Results were expressed as means  $\pm$ SD. Serum IgE levels were given as the geometric mean and range. Analysis of variance (ANOVA) with Bonferroni/Dunn correction was used to compare groups. A p value <0.05 was regarded as statistically significant.

### Results

#### Asthmatic patient characteristics

Asthmatic patient characteristics, pulmonary function tests, and current medications are shown in Table 1. Among the four groups, there were no statistically significant differences in disease duration, sex distribution, number of patients with SDIA or medications used. The

mean serum IgE level in patients under age 49 was the highest of the four groups. The prevalence of atopy was significantly higher in those under age 49 than in those aged between 60 and 69 (p<0.05). The %FVC was significantly lower in those over age 70 than in either those under age 49 (p<0.01) or aged between 50 and 59 (p<0.05), and was also significantly lower in those aged between 60 and 69 than in those under age 49 (p < 0.05). The mean values of %FEV<sub>1</sub> (p<0.05) and FEV<sub>1</sub>/FVC (p < 0.01) were significant lower in those over 70 years of age than in those under age 49. %RV was significantly higher in those over 70 years of age than in either those under age 49 (p< (0.01) or aged between 50 and 59 (p<0.05).

Table 1. Patient characteristics and medication use among groups classified by age

	Asthma					
	≤49 years (n=20)	50·59 years (n=20)	60-69 years (n=20)	70≤ years (n=20)		
Male/female, n	7/13 2/18		5/15	6/14		
Age at onset, years (SD)	22.7 (14.8)	39.3 (12.8)**	50.2 (12.3)**	58.3 (14.1)**.*		
Disease duration, years (SD)	12.0 (7.9)	17.2 (13.7)	14.6 (12.0)	16.4 (13.3)		
Patients with SDIA, n	5	7	6	6		
Serum IgE, IU/ml (range)*	809 (45-5195)	182 (10-1124)**	101 (11-2918)			
Atopy/nonatopy, n	16/4	12/8	7/13	10/10		
FVC,%pred (SD)	105.6 (15.6)	100.0 (12.5)	91.1 (15.1)*	83.8 (16.6)**.1		
FEV <sub>1</sub> ,%pred (SD)	90.3 (12.4)	83.9 (18.3)	81.5 (23.0)	73.3 (20.1)*		
FEV <sub>1</sub> /FVC, % (SD)	77.0 (11.0)	69.2 (11.9)	70.8 (12.8)	63.8 (12.6)**		
RV,%pred (SD)	111.3 (22.9)	119.5 (28.4)	125.6 (26.2)	143.8 (32.6)**		
DLCO,%pred (SD)	104.9 (13.0)	104.7 (17.3)	100.8 (11.9)	89.8 (15.7)*.*		
Medication, n						
Inhaled steroids	18	17	18	19		
Theophylline	12	12	12	14		
LTRA	12	13	12	14		

Values are presented as mean ± SD in parentheses

+: geometric mean and range in parentheses. SDIA = steroid-dependent intractable asthma

FVC = forced vital capacity: %pred = percentage of the predicted value

FEV<sub>1</sub> = forced expiratory volume in one second: RV = residual volume

DLCO = diffusing capacity of the lung for carbon monoxide LTRA = leukotriene receptor antagonists

\*,\*\*: p<0.05, p<0.01 versus asthmatics under age 49


<sup>1</sup>, <sup>1†</sup> : p<0.05, p<0.01 *versus* asthmatics between age 50 and 59

Patients over 70 showed the lowest %DL<sub>co</sub> values of all four age groups. All asthmatic patients were treated with inhaled  $\beta_2$  agonists. The mean dose of inhaled BDP (beclomethasone dipropionate) was 530  $\mu$ g/day for those under age 49, 580  $\mu$ g/day for those aged between 50 and 59, 470  $\mu$ g/day for those aged

between 60 and 69, and 570  $\mu$ g/day for those over age 70. In control subjects, %FVC was  $110.0\pm17.8\%$ , %FEV<sub>1</sub> was  $112.8\pm16.5\%$ , and %FEV<sub>1</sub>/FVC was  $80.5\pm6.5\%$ .

# Correlation between age and HRCT lung densitometry in asthmatics and controls

Figures 1 and 2 show the correlations between subjects' age and HRCT measurements. Significant statistical negative correlations were observed in both asthmatics and controls between age and MLD (Figure 1). The RA<sub>500</sub> had significant positive correlations with subjects' age in both asthmatics and controls (Figure 2).







Figure 1.
re 1. Correlation between age

Figure 1. Correlation between age and MLD in controls (A) and asthmatics (B).






Figure 2.

Figure 2. Correlation between age and  $RA_{550}$  in controls (A) and asthmatics (B).

# Comparison of HRCT lung densitometry between age groups

The results of HRCT lung densitometry in each age group are shown in Table 2. The MLD values were significantly lower in asthmatics compared with controls in subjects aged between 60 and 69 and over age 70. RA<sub>500</sub> values were significantly higher in asthmatics compared with controls in subjects aged between 50 and 59, aged between 60 and 69, and over age 70.

Table 2 Comparison between controls and asthmatics in HRCT lung densitometry classified by age

	MLD (HU)			RA950 (%)		
control	asthma	р	control	asthma	р	
868 (20)	876 (20)	NS	3 4 (2.4)	6 1 (5 6)	NS	
-873 (16)	882 (28)	NS	3.5 (2.6)	8.7 (7.9)	<() ()5	
-871 (21)	-895 (18)	<0.001	4.1 (3.8)	14.7 (11.8)	<0.001	
-885 (20)	-903 (19)	< 0.01	3.6 (6.1)	19.6 (11-1)	< 0.001	
	-868 (20) -873 (16) -871 (21)	-868 (20) 876 (20) -873 (16) -882 (28) -871 (21) -895 (18)	868 (20) 876 (20) NS -873 (16) 882 (28) NS -871 (21) 895 (18) <0.001	868 (20) 876 (20) NS 3 4 (2.4) 873 (16) 882 (28) NS 3.5 (2.6) 671 (21) 895 (18) <0.001 4.1 (3.8)	-868 (20) 876 (20) NS 3.4 (2.4) 6.1 (5.6) -873 (16) 882 (28) NS 3.5 (2.6) 8.7 (7.9) -871 (21) 895 (18) <0.001 4.1 (3.8) 14.7 (11.8)	

Values are presented as mean and SD in parenthesis

MLD = mean lung density

 $RA_{950}$  = relative area of the lungs showing attenuation values less than  $\cdot 950~HU$ 

HU = Hounsfield Units

NS = not significant

# RA950 in patients with SDIA

RA<sub>950</sub> was significantly larger in patients with SDIA aged between 50 and 59 (p<0.001), and between 60 and 69 (p<0.05), compared with the RA<sub>950</sub> in those without SDIA from the same age group. However, RA<sub>950</sub> did not differ significantly between SDIA and non-SDIA in patients over age 70 (Fig. 3).




Figure 3.

Figure 3.  $RA_{990}$  in patients with steroid-dependent intractable asthma (SDIA) ( $\blacksquare$ ) and non-SDIA ( $\square$ )in four groups classified by age.

# Discussion

To clarify the characteristics of the elderly, HRCT lung densitometry (MLD and RA<sub>950</sub>) and pulmonary function (%FEV<sub>1</sub> and %RV) were examined in healthy controls and stable asthmatics classified into four groups according to age ( $\leq$ 49, 50–59, 60–69,  $\geq$ 70 years). In terms of pulmonary function, measurements of airflow limitation (%FEV<sub>1</sub>, FEV<sub>1</sub>/FVC) and %DL<sub>co</sub> were significantly decreased, and %RV was significantly increased in stable asthmatics over 70 years of age compared with the values in those under age 49. The results suggest that pulmonary function (%FVC, %FEV<sub>1</sub>, FEV<sub>1</sub>/FVC, and DL<sub>co</sub>) is clearly decreased in asthmatics over 70 years old.

MLD tended to decrease significantly and RA<sub>950</sub> showed a tendency to increase with aging in both asthmatics and controls. RA950 was significantly higher in asthmatics compared with controls in subjects between 50 and 59, between 60 and 69, and over age 70. RA<sub>950</sub> was also significantly larger in patients with SDIA aged between 50 and 59, and between 60 and 69 years. compared with RA950 in those without SDIA from the same age groups; however, a significant difference was not found in RA950 between SDIA and non-SDIA in elderly patients over 70 years old. The results suggest that RA<sub>950</sub> is mainly influenced by aging in patients over 70. In contrast, RA<sub>950</sub> is affected by severity of the disease as well as aging in patients aged between 50 and 59, and between 69 and 69. The relationship between RA<sub>950</sub> and %FEV<sub>1</sub> or %RV was statistically significant in asthmatics over 50 years of age, but not in those under 49.

Some studies have demonstrated that the duration of asthma is associated with airflow limitation and hyperinflation 25-28). We previously

demonstrated that HRCT lung densitometry was correlated with patient age and severity of asthma<sup>20)</sup>, and that RA<sub>950</sub> in asthmatics with a smoking history indicates the presence of emphysema, whereas in nonsmoking asthmatics it reflects hyperinflation and nonemphysematous expiratory airflow limitation rather than emphysematous lesions<sup>19)</sup>. In the present study, we found significantly decreased %FEV1 and significantly increased %RV and RA950 in patients over 70 years old compared with the values in those under 49. The results show that airflow limitation and hyperinflation as expressed by RA950 were mainly associated with aging in patients aged over 70, and partially associated with disease severity in those between the ages of 50 and 69, but not with disease duration. However, Quadrelli et al. demonstrated that airflow impairment is related not to age itself, but to the duration of asthma<sup>25)</sup>. The discrepancy between their study and the current study may be explained by disease severity. Twenty-four patients with SDIA (30%) were included in our study, whereas none were included in their study. The subjects in our study therefore had a higher disease severity than those in their study.

We used -950HU as the cut-off level between normal lung density area and LAA. Previous studies have used variable levels ranging from -900 to -960 HU<sup>7-15, 24, 29)</sup>. This discrepancy may be attributed to variations between the CT scanning techniques (equipment and reconstruction of images) as well as CT images (conventional vs. high resolution). In our study, using HRCT of 15 healthy controls, we found the mean MLD minus 1 SD to be -949 HU.

Gevenois *et al.* reported that both MLD and RA<sub>950</sub> are influenced by TLC, and to a lesser extent by age in healthy subjects<sup>17)</sup>. This was further supported by a longitudinal study from Soeiima *et al.* who studied images of

nonsmoking subjects over a study period of 5 years<sup>30)</sup>. The present study revealed that an increased RA<sub>550</sub> may be largely influenced by age in patients over 70 years old. In contrast, the present results also show that RA<sub>550</sub> is affected by both aging and disease severity in patients between the ages of 50 and 69.

We conclude that decreased HRCT lung density, airflow limitation and hyperinflation are closely related to age in nonsmoking asthmatics over age 70. The decreased HRCT lung density may represent chronic overinflation in elderly patients with asthma. These results suggest that HRCT scanning may be a useful tool to determine functional characteristics, especially in elderly patients with asthma.

### References

- Ebina M, Takahashi T, Chiba T, et al. Cellular hypertrophy and hyperplasia of airway smooth muscles underlying bronchial asthma.
   A 3-D morphometric study. Am Rev Respir Dis 148: 720-726, 1993.
- 2. Carroll N, Elliot J, Morton A, et al. The structure of large and small airways in nonfatal asthma. Am Rev Respir Dis 147: 405 410, 1993.
- 3. Bousquet J, Chanez P, Lacoste JY, et al. Asthma: a disease remodelling the airways. Allergy 47: 3-11, 1992.
- 4. Paganin F, Trussard V, Seenetterre E, et al. Chest radiography and high resolution computed tomography of the lung in asthma. Am Rev Respir Dis 146: 1064-1087, 1992.
- 5. Angus RM, Davies ML, Cowman MD, et al. Computed tomographic scanning of the lungs in patients with allergic bronchopulmonary aspergillosis and in asthmatic patients with a positive skin test to Aspergillus fumigatus. Thorax 49:586-589, 1994.

- 6. Park JW, Hong YK, Kim CW, et al. High-resolution computed tomography in patients with bronchial asthma: correlation with clinical features, pulmonary functions and bronchial hyperresponsiveness. J Invest Allergol Clin Immunol 7: 186-192, 1997.
- 7. M-ller NL, Staples CA, Miller RR, et al. "Density mask". An objective method to quantitate emphysema using computed tomography. Chest 94: 782-787, 1988.
- 8. Gevenois PA, Maertelaer VD, Vuyst PD, et al. Comparison of computed density and macroscopic morphometry in pulmonary emphysema. Am J Respir Crit Care Med 152:653-657, 1995.
- 9. Gevenois PA, Vuyst PD, Maertelaer VD, et al. Comparison of computed density and microscopic morphometry in pulmonary emphysema. Am J Respir Crit Care Med 154: 187–192, 1996.
- 10. Gevenois PA, Vuyst PD, Sy M, et al. Pulmonary emphysema: quantitative CT during expiration. Radiology 199: 825 829, 1996.
- 11. Sakai N, Mishima M, Nishimura K, et al. An automated method to assess the distribution of low attenuation areas on chest CT scans in chronic pulmonary emphysema patients. Chest 106: 1319-1325, 1994.
- 12. Kinsella M, M-ller NL, Abboud RT, et al. Quantitation of emphysema by computed tomography using a "density mask" program and correlation with pulmonary function tests. Chest 97: 315-321, 1990.
- 13. Nakano Y, Sakai H, Muro S, et al. Comparison of low attenuation areas on CT between inner and outer segments of the lung in COPD patients: Incidence and contribution to lung function. Thorax 54:384-389, 1999.
- 14. Mishima M, Hirai T, Itoh H, et al. Complexity of terminal airspace geometry assessed by lung computed tomography in normal

- subjects and patients with chronic obstructive pulmonary disease. Proc Natl Acad Sci USA 96: 8829-8834, 1999.
- 15. Mishima M, Itoh H, Sakai H, et al. Optimized scanning conditions of high resolution CT in the follow-up of pulmonary emphysema.
  J Comput Assist Tomogr 23: 380-384, 1999.
- 16. Newman KB, Lynch DA, Newman LS, et al. Quantitative computed tomography detects air trapping due to asthma. Chest 1994; 106: 105-109
- 17. Gevenois PA, Scillia P, de Maertelaer V, et al. The effects of age, sex, lung size, and hyperinflation on CT lung densitometry. AJR 167: 1169-1173, 1996.
- 18. Biernacki W, Redpath AT, Best JJ, et al. Measurement of CT lung density in patients with chronic asthma. Eur Respir J 10: 2455 2459, 1997.
- 19. Mitsunobu F, Mifune T, Ashida K, et al. Low attenuation areas of the lungs on high-resolution computed tomography in asthma. J Asthma 38:355-364, 2001.
- Mitsunobu F, Mifune T, Ashida K, et al. The influence of age and disease severity on high resolution CT lung densitometry in asthma. Thorax 56: 851-856, 2001.
- 21. Mitsunobu F, Ashida K, Hosaki Y, et al. Decreased CT lung density during exacerbation of asthma. Eur Respir J 22: 106-112, 2003.
- 22. American Thoracic Society. Standards for the diagnosis and care of patients with chronic obstructive pulmonary disease (COPD) and asthma. Am Rev Respir Dis 136: 225-244, 1987.

- 23. Japanese Society of Chest Diseases. Standards of pulmonary function tests for Japanese. The Japanese Journal of Thoracic Diseases 31: appendix, 1993.
- 24. Miniati M, Filippi E, Falaschi F, et al. Radiologic evaluation of emphysema in patients with chronic obstructive pulmonary disease: chest radiology versus high resolution computed tomography. Am J Respir Crit Care Med 151: 1359-1367, 1995.
- 25. Quadrelli SA, Roncoroni AJ. Is asthma in the elderly really different? Respiration 65:3 47-353, 1998.
- 26. Bailey WC, Higgins DM, Richards BM, et al. Asthma severity: a factor analytic investigation. Am J Med 93: 263-269, 1992.
- 27. Little SA, MacLeod KJ, Chalmers GW, et al. Association of forced expiratory volume with disease duration and sputum neutrophils in chronic asthma. Am J Med. 112: 446-452, 2002.
- 28. Cassino C, Berger KI, Goldring RM, et al. Duration of asthma and physiologic outcomes in elderly nonsmokers. Am J Respir Crit Care Med. 162: 1423-1428, 2000.
- 29. Bae KT, Slone RM, Gierada DS, et al. Patients with emphysema: quantitative CT analysis before and after lung volume reduction surgery. Work in progress. Radiology 203: 705-714, 1997.
- 30. Soejima K, Yamaguchi K, Kohda E, et al. Longitudinal follow-up study of smoking-induced lung density changes by high-resolution computed tomography. Am J Respir Crit Care Med 161: 1264-1273, 2000.

# 高分解能CT lung densitometryにおける高齢者の臨床的特徴

光延文裕,保﨑泰弘,芦田耕三,岩垣尚史, 永田拓也,藤井 誠,高田真吾,横井 正<sup>11</sup>, 浜田全紀<sup>11</sup>,谷崎勝朗

岡山大学医学部・歯学部附属病院三朝医療センター 内科. 11リハビリテーション科

高齢者の病態的特徴を明らかにするために、健常者80例および非喫煙喘息患者80例を対象として、平均肺CT値(MLD)ならびに高分解能CT(HRCT)による一950HU以下の肺 low attenuation area (RA<sub>550</sub>)を評価し、年齢及び肺機能との関連を検討した。1.健常者、喘息患者いずれにおいても年齢とともにMLDは有意に減少し、RA<sub>550</sub>は有意に増加した。MLDは、60-69歳と70歳以上の年齢層において、健常者に比して喘息患者で有意に

低値を示した。RA556は、50-59歳・60-69歳・70 歳以上の年齢層において、健常者に比して喘息患 者で有意に高値を示した。2.喘息患者において、 1 秒量 (%FEV<sub>1</sub>) および 1 秒率 (FEV<sub>1</sub>/FVC) は、 49歳以下の年齢層に比して70歳以上の年齢層で有 意に低値を示した。一方,残気量(%RV)は,50-59歳ならびに49歳以下の年齢層に比して70歳以上 の年齢層で有意に高値を示した。3.50-59歳お よび60-69歳の年齢層では、RA950は、ステロイ ド依存性重症難治性喘息(SDIA)患者において非 SDIA患者に比して有意に高値を示した。しかし、 70歳以上の年齢層では両者に有意の差は認められ なかった。これらの結果より、HRCT上の肺low attenuation areaは高齢者において有意に増加す ること、さらに喘息患者の方が健常者に比してよ り高値を示すことが示唆された。

索引用語:加齡,高分解能CT,低吸収域,平均C T值,肺機能